The Role of the Endocrinologist

  • A. Colao
  • G. Lombardi


Treatment of pituitary tumors has been improved by advances in trans-sphenoidal surgery and radiotherapy and by the development of remarkably effective drugs for PRL-, GH-, TSH- and ACTH-secreting tumors. The primary therapeutic objectives are to normalize hormone excess, to shrink tumor size and possibly to prevent damage to normal pituitary tissue and surrounding parasellar structures, especially the optic chiasm. To achieve these ambitious goals the approach integrates knowledge in endocrinology, neurosurgery, radiotherapy, ophthalmology and several other specialties. This chapter aims at focusing the role of the endocrinologist in the approach to treatment of functioning and nonfunctioning pituitary tumors. Beside the widely accepted primary medical treatment of prolactinomas, we would like to emphasize the novel pharmacologic alternatives to apply after an unsuccessful surgery or while waiting for the effects of radiotherapy as well as the potential usefulness of a pre-surgical treatment with somatostatin analogues and/or dopamine-agonists in patients with GH-, TSH- and ACTH-secreting adenomas.


Pituitary Adenoma Dopamine Agonist Acromegalic Patient Transsphenoidal Surgery Inferior Petrosal Sinus Sampling 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abosh A, Tyrrell JB, Lamborn KR, Hannegan L T, Applebury CB, Wilson CB (1998) Transsphenoidal microsurgery for growth-hormone secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 72: 1175–1176Google Scholar
  2. 2.
    Abs R, Versholst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A (1998) Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83: 374–378PubMedCrossRefGoogle Scholar
  3. 3.
    Andersen M, Bjerret P, Schroder HD, Edal A, Hoilund-Carlsen PF, Pedersen PH, Hagen C (2001) In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas. Clin Endocrinol 54:23–30CrossRefGoogle Scholar
  4. 4.
    Aron DC, Tyrrell B, Wilson CB (1995) Pituitary tumors: current concepts in diagnosis and management. World J Med 162: 340–352Google Scholar
  5. 5.
    Baldelli R, Colao A, Razzore P, Jaffrain-Rea M-L, Marzullo P, Ciccarelli E, Ferretti E, Ferone D, Gaia D, Camanni F, Lombardi G, Tamburrano G (2000) Two-year follow-up of acromegalic patients treated with SR-lanreotide 30mg. J Clin Endocrinol Metab 85: 4099–4103PubMedCrossRefGoogle Scholar
  6. 6.
    Baldelli R, Ferretti E, Jaffrain-Rea ML, Jacobellis G, Minniti G, Caracciolo B, Moroni C, Cassone R, Gulino A, Tamburrano G (1999) Cardiac effects of slow-release lanreotide, a slowrelease somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab 84: 575–532CrossRefGoogle Scholar
  7. 7.
    Barkan A (1997) Acromegalic arthropathy and sleep apnea. J Endocrinol 155: S41–S44PubMedGoogle Scholar
  8. 8.
    Barkan A, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP, Beitins IZ (1988) Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 67: 1040–1048PubMedCrossRefGoogle Scholar
  9. 9.
    Barkan A, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, Sandler HM (1997) Pituitary irradiation is ineffective in normalizing insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 82: 3187–3191PubMedCrossRefGoogle Scholar
  10. 10.
    Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD (1996) Thryrotropinsecreting pituitary tumors. Endocrine Rev 17: 610–638Google Scholar
  11. 11.
    Bevan JS, Webster J, Burke CW, Scanlon MF (1992) Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13: 221–235Google Scholar
  12. 12.
    Biermasz NR, van Dulken H, Roelfsema F (1999) Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab 84: 3551–3555PubMedCrossRefGoogle Scholar
  13. 13.
    Biller BMK, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, Schoenfelder JR, Klibanski A (1996) Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 81: 2338–2343PubMedCrossRefGoogle Scholar
  14. 14.
    Bochicchio D, Losa M, Buchfelder M (1995) Factors influencing the immediate and late outcome of cushing’s disease treated by transsphenoidal surgery: a retrospective study by the European Cushing’s disease survey group. J Clin Endocrinol Metab 80: 3114–3120PubMedCrossRefGoogle Scholar
  15. 15.
    Boscaro M, Barzon L, Fallo F, Sonino N (2001) Cushing’s syndrome. Lancet 357: 783–791PubMedCrossRefGoogle Scholar
  16. 16.
    Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD (1999) Thryotropinsecreting piuitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab 84: 476–486PubMedCrossRefGoogle Scholar
  17. 17.
    Brue T, Pellegrini I, Priou A, Morange I, Jaquet P (1992) Prolactinomas and resistance to dopamine-agonists. Horm Res 38: 84–89PubMedCrossRefGoogle Scholar
  18. 18.
    Cappabianca P, Alfieri A, Colao A, Ferone D, Lombalidi G, de Divitiis E (1999) Endoscopic endonasal transsphenoidal approach: an additional reason in support of surgery in the management of pituitary lesions. Skull Base Surg 9: 109–117PubMedCrossRefGoogle Scholar
  19. 19.
    Cappabianca P, Alfieri A, de Divitiis E, Tschabitscher M (2001) Atlas of endoscopic anatomy for endonasal intracranial surgery. Springer, Wien New York, pp 134CrossRefGoogle Scholar
  20. 20.
    Cappabianca P, Cavallo LM, Colao A, de Divitiis E (2002) Surgical complications associated with the endoscopic endonasal transsphenoidal approach for pituitary adeomas. J Neurosurg 97: 293–298PubMedCrossRefGoogle Scholar
  21. 21.
    Chanson P, Timsit J, Benoit O, Augendre B, Moulonguet M, Guillausseau PG, Warnet A, Lubetzki J (1986) Rapid improvement of sleep apnoea of acromegaly after short term treatment with somatostatin analogue SMS 201-995. Lancet 1: 1270–1271PubMedCrossRefGoogle Scholar
  22. 22.
    Chanson P, Weintraub BD, Harris AG (1993) Octreotide therapy for thyroid-stimulating hormonesecreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 119: 236–240PubMedGoogle Scholar
  23. 23.
    Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B, Lombardi G (1997) Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 82: 518–523PubMedCrossRefGoogle Scholar
  24. 24.
    Colao A, Ferone D, Cappabianca P, De Caro M, Marzullo P, Monticelli A, Alfieri A, Merola B, Can A, de Oivitiis E, Lombardi G (1997) Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82: 3308–3314PubMedCrossRefGoogle Scholar
  25. 25.
    Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82: 3574–3579PubMedCrossRefGoogle Scholar
  26. 26.
    Colao A, Cerbone G, Cappabianca P, Ferone D, Alfieri A, Di Salle F, Faggiano A, Merola B, de Oivitiis E, Lombardi G (1998) Effect of surgery and radiotherapy in visual and endocrine function in nonfunctioning pituitary adenomas. J Endocrinollnvest 21: 284–290Google Scholar
  27. 27.
    Colao A, Lombardi G (1998) GH and PRL excess. Lancet 352: 1455–1461PubMedCrossRefGoogle Scholar
  28. 28.
    Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G (1999) Pituitary uptake of In-111-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas. J Endocrinol Invest 22: 176–183PubMedGoogle Scholar
  29. 29.
    Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, Salvatore M, Lombardi G (1999) Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 84: 17–23PubMedCrossRefGoogle Scholar
  30. 30.
    Colao A, Pivonello P, Spiezia S, Faggiano A, Marzullo P, Cerbone G, Ferone D, Filippella M, Siciliani M, Lombardi G (1999) Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab 84: 2664–2672PubMedCrossRefGoogle Scholar
  31. 31.
    Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, Lucci R, Lombardi G (2000) Hormone levels and tumor size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically nonfunctioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-Methoxybenzamide. Clin Endocrinol 52: 437–445CrossRefGoogle Scholar
  32. 32.
    Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive than in patients pre-treated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85: 2247–2252PubMedCrossRefGoogle Scholar
  33. 33.
    Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G (2000) Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR® in acromegaly. J Clin Endocrinol Metab 86: 3132–3140CrossRefGoogle Scholar
  34. 34.
    Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86: 2779–2786PubMedCrossRefGoogle Scholar
  35. 35.
    Colao A, Faggiano A, Pivonello R, Pecori Giraldi F, Cavagnini F, Lombardi G, and The Study Group of the Italian Endocrinology Society on the Pathophysiology of the HypothalamicPituitary-Adrenal Axis (2001) Inferior petrosal sinus sampling in the differential diagnosis of Cushing’s syndrome: Results of an Italian multicentre study. Eur J Endocrinol 144: 499–507PubMedCrossRefGoogle Scholar
  36. 36.
    Colao A, Ferone D, Lombardi G, Lastoria S (2002) 99mTechnetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy. Clin Endocrinol 56: 713–721CrossRefGoogle Scholar
  37. 37.
    Colao A, Di Sarno A, Pivonello R, Di Somma C, Lombardi G (2002) Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 11: 787–800PubMedCrossRefGoogle Scholar
  38. 38.
    Colao A, Marzullo P, Lombardi G, and The Multicenter Italian Study Group on Lanreotide (2002) Effect of a six month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol 146: 303–309PubMedCrossRefGoogle Scholar
  39. 39.
    Colao A, Di Sarno A, Cappabianca P, Briganti F, Pivonello R, Di Somma C, Faggiano A, Biondi B, Lombardi G (2002) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol (in press)Google Scholar
  40. 40.
    Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G (2002) Remission of hyperprolactinemia after long-term cabergoline withdrawal in macroprolactinomas and microprolactinomas: a four year observational, analytical and prospective study. J Clin Endocrinol (in press)Google Scholar
  41. 41.
    Colao A, Spinelli L, Cuocolo A, Spiezia S, Pivonello R, Di Somma C, Bonaduce D, Salvatore M, Lombardi G (2002) Cardiovascular consequences of early-onset Growth Hormone excess. J Clin Endocrinol Metab 87: 3097–3104PubMedCrossRefGoogle Scholar
  42. 42.
    De Bruin TWA, Kwekkeboom DJ, van’t Verlaat JW, Reubi JC, Krenning EP, Lamberts SW, Croughs RJ (1992) Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J Clin Endocrinol Metab 75: 1310–1317PubMedCrossRefGoogle Scholar
  43. 43.
    de Divitiis E, Cappabianca P (2002) Endoscopic endonasal transsphenoidal surgeru. In: Pickard JD (ed) Advances and technical standards in neurosurgery. Springer, Wien New York, vol 27, pp 137–177CrossRefGoogle Scholar
  44. 44.
    Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82: 2102–2107PubMedCrossRefGoogle Scholar
  45. 45.
    De La Torre NG, Wass JA, Turner HE (2002) Antiangiogenic effects of somatostatin analogues. Clin Endocrinol 57: 425–441CrossRefGoogle Scholar
  46. 46.
    Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86: 5256–5261PubMedCrossRefGoogle Scholar
  47. 47.
    Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW, Chrousos GP (1997) The longitudinal course of psychopathology in Cushing’s syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 82: 912–919PubMedCrossRefGoogle Scholar
  48. 48.
    Drake WM, Perry LA, Hinds CJ, Lowe DG, Reznek RH, Besser GM (1998) Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing’s syndrome and peritonitis. J Clin Endocrinol Metab 83: 3542–3544PubMedCrossRefGoogle Scholar
  49. 49.
    Ebersold MJ, Quast LM, Laws ER, Scheitauer B, Randall RV (1986) Long-term results in transsphenoidal removal of nonfunctioning pituitary adenoma. J Neurosurg 64: 713–719PubMedCrossRefGoogle Scholar
  50. 50.
    Epaminonda P, Porretti S, Cappiello V, Beck-Peccoz P, Faglia G, Arosio M (2001) Efficacy of radiotherapy in normalizing serum IGF-I, acid-labile subunit (ALS) and IGFBP-3 levels in acromegaly. Clin Endocrinol 55: 183–189CrossRefGoogle Scholar
  51. 51.
    Estrada J, Boronat M, Mielgo M, Magallon R, Millan I, Diez S, Lucas T, Barcelo B (1997) The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing’s disease. N Engl J Med 336: 172–177PubMedCrossRefGoogle Scholar
  52. 52.
    Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M, Lombardi G (1998) Correlation of scintigraphic results using 1231-Methoxibenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. J Clin Endocrinol Metab 83: 248–252PubMedCrossRefGoogle Scholar
  53. 53.
    Ferrari C, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, Mucci M, Muratori M, Musatti L, Verbessem G, Scanlon MF (1997) Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol 46: 409–413CrossRefGoogle Scholar
  54. 54.
    Findling JW, Raff H (1999) Newer diagnostic techniques and problems in Cushing’s disease. Endocrinol Metab Clin North Am 28: 191–210PubMedCrossRefGoogle Scholar
  55. 55.
    Freda PU, Post KD, Wardlaw SL (1996) Unusual causes of sellar/parasellar masses in a large transsphenoidal surgical series. J Clin Endocrinol Metab 81: 3455–3459PubMedCrossRefGoogle Scholar
  56. 56.
    Freda PU, Wardlaw SL, Post KD (1998) Long.term endocrinologic follow-up after transsphenoidal surgery for acromegaly. J Neurosurg 89: 353–358PubMedCrossRefGoogle Scholar
  57. 57.
    Freda PU, Wardlaw SL (1999) Diagnosis and treatment of pituitary tumors. J Clin Endocrinol Metab 84: 3859–3866PubMedCrossRefGoogle Scholar
  58. 58.
    Fukuda T, Yokoyama N, Tamai M, Imaizumi M, Kimura H, Tominaga T, Ashizawa K, Kiriyama T, Yoshimine H, Ohishi K, Eguchi K (1998) Thyrotropin secreting pituitary adenoma effectively treated with octreotide. Intern Med 37: 1027–1030PubMedCrossRefGoogle Scholar
  59. 59.
    Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM (1994) Effects of a slowrelease formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol 40: 421–428CrossRefGoogle Scholar
  60. 60.
    Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85: 526–529PubMedCrossRefGoogle Scholar
  61. 61.
    Gomez MT, Magiakou MA, Mastorakos G, Chrousos GP (1993) The pituitary corticotroph is not the rate-limiting step in the postoperative recovery of the hypothalamic-pituitary-adrenal axis in patients with Cushing’s syndrome. J Clin Endocrinol Metab 77: 173–177PubMedCrossRefGoogle Scholar
  62. 62.
    Harris PE, Afshar F, Coates P, Doniach I, Wass JA, Besser GM, Grossman A (1989) The effects of transsphenoidal surgery on endocrine function and visual fields in patients with functionless pituitary adenomas. QJ Med 71: 417–427Google Scholar
  63. 63.
    Hedner P, Valdemarsson S (1989) Reduced size of a hormonally silent pituitary adenoma during treatment with CV 205-502, a new dopamine agonist mainly stimulating D2 receptors. Neurosurgery 25: 948–950PubMedCrossRefGoogle Scholar
  64. 64.
    Hradec J, Kral J, Janota T, Krsek M, Hana V, Marek J, Malik M (1999) Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow release somatostatin analog). Am J Cardiol 83: 1506–1509PubMedCrossRefGoogle Scholar
  65. 65.
    Jane JA, Laws ER (2001) The surgical management of pituitary adenomas in a series of 3,093 patients. J Am Coli Surg 193: 651–659Google Scholar
  66. 66.
    Jho HD, Carrau RL (1996) Endoscopic endonasal transsphenoidal surgery: experience with 50 patients. Neurosurgical Focus 1(2): 1–10CrossRefGoogle Scholar
  67. 67.
    Jho HD, Carrau RL (1997) Endoscopic endonasal transsphenoidal surgery: experience with 50 patients. J Neurosurg 87: 44–51PubMedCrossRefGoogle Scholar
  68. 68.
    Johnston DG, Hall K, Kendall-Taylor P, Patrick D, Watson M, Cook DB (1984) Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with highdefinition computerized tomography. Lancet 2: 187–192Google Scholar
  69. 69.
    Katznelson L, Alexander JM, Klibanski A (1993) Clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 76: 1089–1094PubMedCrossRefGoogle Scholar
  70. 70.
    Kreutzer J, Vance ML, Lopes MB, Laws ER (2001) Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86: 4027–4072CrossRefGoogle Scholar
  71. 71.
    Kwekkboom DJ, Lamberts SWJ (1992) Long-term treatment with dopamine agonist CV 205-502 of patients with clinically non-functioning, gonadotroph, or a-subunit secreting pituitary adenoma. Clin Endocrinol 36: 171–176CrossRefGoogle Scholar
  72. 72.
    Lamberts SWJ, Birkenhager JC (1976) Bromocriptine in Nelson’s syndrome and Cushing’s disease. Lancet 2: 811PubMedCrossRefGoogle Scholar
  73. 73.
    Lamberts SWJ, Zweens M, Verschoor L, del Pozo E (1986) A comparison among the growth hormone lowering effect of the somatostatin analog, SMS 201-995, bromocriptine and combination of both drugs. J Clin Endocrinol Metab 63: 16–19PubMedCrossRefGoogle Scholar
  74. 74.
    Lamberts SWJ, Krenning EP, Reubi JC (1990) The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12: 450–481CrossRefGoogle Scholar
  75. 75.
    Lamberts SWJ, van der Lely A-J, de Herder WW, Hofland LJ (1996) Octreotide. N Engl J Med 334: 246–254PubMedCrossRefGoogle Scholar
  76. 76.
    Lambooij AC, Kuijpers RW, van Lichtenauer~Kaligis EG, Kliffen M, Baarsma GS, van Hagen PM, Mooy CM (2000) Somatostatin receptor 2A expression in choroidal neovascularization secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 41: 2329–2335PubMedGoogle Scholar
  77. 77.
    Laws ER, Reitmeyer M, Thapar K, Vance ML (2002) Cushing’s disease resulting from pituitary corticotrophic microadenoma. Treatment results from transsphenoidal microsurgery and gamma knife radiosurgery. Neurochirurgie 48: 294–299Google Scholar
  78. 78.
    Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JRE, Shalet SM (1998) The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol 49: 653–657CrossRefGoogle Scholar
  79. 79.
    Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton MI (1989) Hypopituitarism following external radiotherapy for pituitary tumors in adults. QJ Med 70: 145–160Google Scholar
  80. 80.
    Losa M, Magnani P, Mortini P, Persani L, Acerno S, Giugni E, Songini C, Fazio F, Beck-Peccoz P, Giovanelli M (1997) Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels. Eur J Nucl Med 24: 728–731PubMedGoogle Scholar
  81. 81.
    Lucas-Morante T, Garcia-Uria J, Estrada J, Saucedo G, Cabello A, Alcaniz J, Barcelo B (1994) Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. J Neurosurg 81: 10–14PubMedCrossRefGoogle Scholar
  82. 82.
    Mampalam TJ, Tyrrell B, Wilson CB (1988) Transsphenoidal microsurgery for Cushing disease: a report of 216 cases. Ann Intern Med 109: 487–493PubMedGoogle Scholar
  83. 83.
    Marzullo P, Ferone D, Di Somma C, Pivonello R, Filippella M, Lombardi G, Colao A (1999) Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1: 115–120PubMedCrossRefGoogle Scholar
  84. 84.
    Melmed S, Jackson I, Kleinberg D, Klibanski A (1998) Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 83: 2646–2652PubMedCrossRefGoogle Scholar
  85. 85.
    Melmed S, Casanueva FF, Cavagnini F, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A (2002) Guidelines for acromegaly management. J Clin Endocrinol Metab 87: 4054–4058PubMedCrossRefGoogle Scholar
  86. 86.
    Mercado-Asis LB, Yasuda K, Murayama M, Mune T, Morita H, Miura K (1992) Beneficial effects of high daily dose bromocriptine in Cushing’s disease. Endocrinol Jpn 39: 385–395PubMedCrossRefGoogle Scholar
  87. 87.
    Molitch ME, Thorner MO, Wilson C (1997) Management of prolactinomas. J Clin Endocrinol Metab 82: 996–1000PubMedCrossRefGoogle Scholar
  88. 88.
    Molitch ME (2001) Disorders of prolactin secretion. Endocrinol Metab Clin North Am 30: 585–610PubMedCrossRefGoogle Scholar
  89. 89.
    Moriando P, Travaglini P, Nissim M, Conti A, Faglia G (1985) Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J Clin Endocrinol Metab 60: 764–772CrossRefGoogle Scholar
  90. 90.
    Newell-Price J, Trainer P, Besser M, Grossman A (1998) The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 19: 647–672PubMedCrossRefGoogle Scholar
  91. 91.-Newman CB, Hurley AM, Kleinberg DL (1989) Effect of CV 205-502 in hyperprolactinemic patients intolerant to bromocriptine. Clin Endocrinol 31: 391–400CrossRefGoogle Scholar
  92. 92.
    Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL (1998) Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 83: 3034–3040PubMedCrossRefGoogle Scholar
  93. 93.
    Nomikos P, Buchfelder M, Fahlbusch R (2001) Current management of prolactinomas. J Neurooncol 54: 139–150PubMedCrossRefGoogle Scholar
  94. 94.
    Passos VQ, Souza JJS, Musolino NRC, Bronstein MD (2002) Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 87: 3578–3582PubMedCrossRefGoogle Scholar
  95. 95.
    Pereira JL, Rodriguez-Puras MJ, Leal-Cerro A, Martinez A, Garcia-Luna PP, Gavilan I, Pumar A, Astorga R (1991) Acromegalic cardiopathy improves after treatment with increasing doses of octreotide. J Endocrinol Invest 14: 17–23PubMedGoogle Scholar
  96. 96.
    Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G, Colao A (1999) Complete remission of Nelsons’ syndrome after 1 year treatment with cabergoline: a case report. J Endocrinol Invest 22: 860–865PubMedGoogle Scholar
  97. 97.
    Plockinger U, Reichel M, Fett U, Saeger W, Quabbe HJ (1994) Preoperative octreotide treatment of growth-hormone secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 79: 1416–1423PubMedCrossRefGoogle Scholar
  98. 98.
    Powell JS, Wardlaw SL, Post KD, Freda PU (2000) Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. J Clin Endocrinol Metab 85: 2068–2071PubMedCrossRefGoogle Scholar
  99. 99.
    Rasmussen C, Brownell J, Berght T (1991) Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502. Acta Endocrinol 125: 170–176PubMedGoogle Scholar
  100. 100.
    Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC (2000) Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288(5463): 154–157PubMedCrossRefGoogle Scholar
  101. 101.
    Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68: 412–418PubMedCrossRefGoogle Scholar
  102. 102.
    Sheehan JM, Vance ML, Sheehan JP, Ellegala DB, Laws ER Jr (2000) Radiosurgery for Cushing’s disease after failed transsphenoidal surgery. J Neurosurg 93: 738–742PubMedCrossRefGoogle Scholar
  103. 103.
    Shomali ME, Katznelson L (1999) Medical therapy for gonadotroph and thyrotroph tumors. Endocrinol Metab Clin North Am 28: 223–240PubMedCrossRefGoogle Scholar
  104. 104.
    Sonino N (1987) The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 317:812–818PubMedCrossRefGoogle Scholar
  105. 105.
    Sonino N, Boscaro M (1999) Medical therapy for Cushing’s disease. Endocrinol Metab Clin North Am 28: 211–222PubMedCrossRefGoogle Scholar
  106. 106.
    Spinas GA, Zapf J, Landolt AM, Stuckmann G, Froesch ER (1987) Pre-operative treatment of 5 acromegalics with a somatostatin analogue: endocrine and clinical observations. Acta Endocrinol 114: 249–256PubMedGoogle Scholar
  107. 107.
    Stevenaert A, Harris AG, Kovacs K, Beckers A (1992) Presurgical octreotide treatment in acromegaly. Metabolism 41: 51–58PubMedCrossRefGoogle Scholar
  108. 108.
    Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT (1998) Long-term mortality after transphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 72: 1175–1176Google Scholar
  109. 109.
    Swearingen B, Biller BMK, Barker FG II, Katznelson L, Grinspoon L, Hlibanski A, Zervas NT (1999) Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med 130: 821–824PubMedGoogle Scholar
  110. 110.
    Thomson JA, Gray CE, Teasdale GM (2002) Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lessons from long-term follow-up. Neurosurgery 50: 36–39PubMedGoogle Scholar
  111. 111.
    Thuesen L, Christensen SE, Weeke J, Ørskov H, Henningsen P (1989) The cardiovascular effects of octreotide treatment in acromegaly: an echocardiographic study. Clin Endocrinol 30: 619–625CrossRefGoogle Scholar
  112. 112.
    Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342: 1171–1177PubMedCrossRefGoogle Scholar
  113. 113.
    Turner TH, Cookson JC, Wass JAH, Drury PL, Price PA, Besser GM (1984) Psychotic reactions during treatment of pituitary tumours with dopamine agonist. Br Med J 289: 1101–1103CrossRefGoogle Scholar
  114. 114.
    Turner HE, Stratton JM, Byrne JV, Adams CB, Wass JA (1999) Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation-a follow-up study. Clin Endocrinol 51: 281–284CrossRefGoogle Scholar
  115. 115.
    van der Lely AJ, de Herder WW, Lamberts SWJ (1997) The role of radiotherapy in acromegaly. J Clin Endocrinol Metab 82: 3185–3186PubMedCrossRefGoogle Scholar
  116. 116.
    van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO (2001) Long term treatment of acromegaly with pegvisomant, a growth hormone antagonist. Lancet 358: 1754–1759PubMedCrossRefGoogle Scholar
  117. 117.
    van der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA, Lamberts SW (2001) Control of tumor size and disease activity during co-treatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 86: 478–481PubMedCrossRefGoogle Scholar
  118. 118.
    Van’t Verlaat JW, Croughs RJ (1991) Withdrawal of bromocriptine after long-term therapy for macroprolactinomas: effect on plasma prolactin and tumor size. Clin Endocrinol 34: 175–178CrossRefGoogle Scholar
  119. 119.
    Vance M, Evans W, Thorner M (1984) Drugs five years later. Bromocriptine. Ann Intern Med 100: 78–91Google Scholar
  120. 120.
    Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84: 2518–2522PubMedCrossRefGoogle Scholar
  121. 121.
    Vilar L, Burke CW (1994) Quinagolide efficacy and tolerability in hyperprolactinemic patients who are resistant to or intolerant of bromocriptine. Clin Endocrinol 41: 821–826CrossRefGoogle Scholar
  122. 122.
    Wang C, Lam KSL, Ma TC, Chan T, Liu MY, Yeung RTI (1987) Long-term treatment of hyperprolactinemia with bromocriptine: effect of drug withdrawal. Clin Endocrinol 27: 363–371CrossRefGoogle Scholar
  123. 123.
    Warnet A, Harris AG, Renard E, Martin D, James-Deidier A, Chaumet-Riffaud P, and the French Multicenter Octreotide Study Group (1997) A prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropinsecreting pituitary adenomas. Neurosurgery 41: 786–797PubMedCrossRefGoogle Scholar
  124. 124.
    Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF, for the Cabergoline Comparative Study Group (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 331: 904–909PubMedCrossRefGoogle Scholar
  125. 125.
    Weckbecker G, Briner U, Lewis I, Bruns C (2002) SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the Growth Hormone/Insulin-Like Growth Factor-I axis in rats, primates, and dogs. Endocrinology 143: 4123–4130PubMedCrossRefGoogle Scholar
  126. 126.
    Whitehead HM, Beacom R, Sheridan B, Atkinson AB (1990) The effect of cyproheptadine and/ or bromocriptine on plasma ACTH levels in patients cured of Cushing’s disease by bilateral adrenalectomy. Clin Endocrinol 32: 193–201CrossRefGoogle Scholar
  127. 127.
    Zarate A, Canales ES, Cano C, Pilonieta CJ (1983) Follow-up of patients with prolactinoma after discontinuation of long-term therapy with bromocriptine. Acta Endocrinol 104: 139–142PubMedGoogle Scholar
  128. 128.
    Zhang N, Pan L, Wang EM, Dai JZ, Wang BJ, Cai PW (2000) Radiosurgery for growth hormone-producing pituitary adenomas. J Neurosurg 93[Suppl 3]: 6–9PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • A. Colao
  • G. Lombardi

There are no affiliations available

Personalised recommendations